| Assessment Status | Rapid Review Complete |
| HTA ID | 25062 |
| Drug | Risdiplam |
| Brand | Evrysdi® |
| Indication | Risdiplam is indicated for the treatment of 5q spinal muscular atrophy (SMA) in patients with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies. The Applicant is seeking reimbursement in a subpopulation of the licensed population as follows: • Patients aged 18 years and older with a clinical diagnosis of SMA Type 2 or Type 3 or with one to four SMN2 copies, who have not previously been treated with a disease modifying therapy. |
| Assessment Process | |
| Rapid review commissioned | 17/10/2025 |
| Rapid review completed | 20/11/2025 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that risdiplam for the proposed subpopulation not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Next steps: The NCPE Assessment Report and recommendation, will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Further information on this process may be found here.
Further information on the status of this decision may be found here.